Get started
Jasper Therapeutics, Inc.Jasper Therapeutics, Inc.Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

JSPR chart


Full chart

JSPR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪325.68 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.75 USD
Net income (FY)
‪−64.47 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪11.23 M‬
Beta (1Y)
3.43

Employees


Employees (FY)
45
Change (1Y)
+10 +28.57%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.43 M‬ USD

About Jasper Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Ronald A. Martell
Website
jaspertherapeutics.com
Headquarters
Redwood City
Founded
2018
FIGI
BBG00QPZNP97
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

JSPR news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of JSPR is 21.71 USD — it has decreased by −1.85% in the past 24 hours. Watch Jasper Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Jasper Therapeutics, Inc. stocks are traded under the ticker JSPR.
JSPR stock has fallen by −0.46% compared to the previous week, the month change is a −1.09% fall, over the last year Jasper Therapeutics, Inc. has showed a 274.50% increase.
We've gathered analysts' opinions on Jasper Therapeutics, Inc. future price: according to them, JSPR price has a max estimate of 90.00 USD and a min estimate of 60.00 USD. Watch JSPR chart and read a more detailed Jasper Therapeutics, Inc. stock forecast: see what analysts think of Jasper Therapeutics, Inc. and suggest that you do with its stocks.
JSPR reached its all-time high on Oct 15, 2021 with the price of 188.80 USD, and its all-time low was 3.86 USD and was reached on Dec 20, 2022. View more price dynamics on JSPR chart.
See other stocks reaching their highest and lowest prices.
JSPR stock is 5.55% volatile and has beta coefficient of 3.43. Track Jasper Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Jasper Therapeutics, Inc. there?
Today Jasper Therapeutics, Inc. has the market capitalization of ‪325.68 M‬, it has decreased by −1.47% over the last week.
Yes, you can track Jasper Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Jasper Therapeutics, Inc. is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
JSPR earnings for the last quarter are −1.24 USD per share, whereas the estimation was −1.07 USD resulting in a −15.75% surprise. The estimated earnings for the next quarter are −1.26 USD per share. See more details about Jasper Therapeutics, Inc. earnings.
Jasper Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
JSPR net income for the last quarter is ‪−18.64 M‬ USD, while the quarter before that showed ‪−14.58 M‬ USD of net income which accounts for −27.80% change. Track more Jasper Therapeutics, Inc. financial stats to get the full picture.
No, JSPR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 45.00 employees. See our rating of the largest employees — is Jasper Therapeutics, Inc. on this list?
Like other stocks, JSPR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Jasper Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Jasper Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Jasper Therapeutics, Inc. stock shows the neutral signal. See more of Jasper Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.